2022
Moving from Evidence to Implementation of Breakthrough Therapies for Diabetic Kidney Disease
Tuttle KR, Wong L, St. Peter W, Roberts G, Rangaswami J, Mottl A, Kliger A, Harris RC, Gee PO, Fowler K, Cherney D, Brosius FC, Argyropoulos C, Quaggin SE. Moving from Evidence to Implementation of Breakthrough Therapies for Diabetic Kidney Disease. Clinical Journal Of The American Society Of Nephrology 2022, 17: 1092-1103. PMID: 35649722, PMCID: PMC9269635, DOI: 10.2215/cjn.02980322.Commentaries, Editorials and LettersConceptsDiabetic kidney diseaseKidney disease careKidney diseaseHealth care systemDisease careKidney failureGlucagon-like peptide-1 receptor agonistsSodium-glucose cotransporter 2 inhibitorsPeptide-1 receptor agonistsAngiotensin-converting enzyme inhibitorBreakthrough therapiesMajor public health challengeHealth care system supportCare systemAngiotensin receptor blockersCotransporter 2 inhibitorsHalf of patientsPocket drug costsIndividual health care systemsPublic health challengeHealth care professionalsValue-based careEligible patientsMineralocorticoid antagonistsCardiovascular eventsMedicare Coverage and Out-of-Pocket Costs of Quadruple Drug Therapy for Heart Failure
Faridi K, Dayoub E, Ross J, Dhruva S, Ahmad T, Desai N. Medicare Coverage and Out-of-Pocket Costs of Quadruple Drug Therapy for Heart Failure. Journal Of The American College Of Cardiology 2022, 79: 2516-2525. PMID: 35738713, DOI: 10.1016/j.jacc.2022.04.031.Peer-Reviewed Original ResearchConceptsSodium-glucose cotransporter 2 inhibitorsAngiotensin receptor neprilysin inhibitorQuadruple therapyOOP costsMedicare coveragePocket costsAngiotensin-converting enzyme inhibitorPrior authorizationAngiotensin receptor blockersQuadruple drug therapyCotransporter 2 inhibitorsMineralocorticoid receptor antagonistsReduced ejection fractionDrug plansReceptor blockersEjection fractionHeart failureDrug therapyReceptor antagonistPrescription drug plansMedicare patientsEnzyme inhibitorsTherapyRegimensMedication prices
2021
Guideline-Directed Medical Therapy in Patients with Chronic Kidney Disease Undergoing Peripheral Vascular Intervention
Jelani QU, Llanos-Chea F, Bogra P, Trejo-Paredes C, Huang J, Provance JB, Turner J, Anantha-Narayanan M, Sheikh AB, Smolderen KG, Mena-Hurtado C. Guideline-Directed Medical Therapy in Patients with Chronic Kidney Disease Undergoing Peripheral Vascular Intervention. American Journal Of Nephrology 2021, 52: 845-853. PMID: 34706363, DOI: 10.1159/000519484.Peer-Reviewed Original ResearchConceptsComorbid chronic kidney diseaseGuideline-directed medical therapyPeripheral vascular interventionsCritical limb ischemiaMedian odds ratioMedical therapyPrescription ratesVascular interventionsHigh riskUse of GDMTAdjusted median odds ratioVascular Quality Initiative databaseAngiotensin-converting enzyme inhibitorAngiotensin receptor blockersChronic kidney diseaseLower prescription ratesPoor clinical outcomeCKD groupCKD statusAntiplatelet therapyReceptor blockersLimb ischemiaLimb outcomesClinical outcomesMedical managementRisk reduction and pharmacological strategies to prevent progression of aortic aneurysms
Weininger G, Chan SM, Zafar M, Ziganshin BA, Elefteriades JA. Risk reduction and pharmacological strategies to prevent progression of aortic aneurysms. Expert Review Of Cardiovascular Therapy 2021, 19: 619-631. PMID: 34102944, DOI: 10.1080/14779072.2021.1940958.Peer-Reviewed Original ResearchConceptsAortic aneurysmAbdominal aortic aneurysmß-blockersAngiotensin II receptor blockersAngiotensin-converting enzyme inhibitorAnti-platelet medicationDifferent pharmacologic therapiesII receptor blockersAortic aneurysm patientsThoracic aortic aneurysmRisk reductionAortic aneurysm growthPharmacologic managementReceptor blockersPharmacologic therapyMedical therapySurgical interventionAneurysm patientsMiscellaneous drugsAneurysm diseasePharmacological strategiesSyndrome patientsMarfan syndromeEnzyme inhibitorsAneurysms
2020
Neurohormonal Blockade and Clinical Outcomes in Patients With Heart Failure Supported by Left Ventricular Assist Devices
McCullough M, Caraballo C, Ravindra NG, Miller PE, Mezzacappa C, Levin A, Gruen J, Rodwin B, Reinhardt S, van Dijk D, Ali A, Ahmad T, Desai NR. Neurohormonal Blockade and Clinical Outcomes in Patients With Heart Failure Supported by Left Ventricular Assist Devices. JAMA Cardiology 2020, 5: 175-182. PMID: 31738366, PMCID: PMC6865330, DOI: 10.1001/jamacardio.2019.4965.Peer-Reviewed Original ResearchConceptsKansas City Cardiomyopathy Questionnaire scoreNeurohormonal blockadeAngiotensin receptor blockersVentricular assist deviceQuality of lifeMineralocorticoid antagonistsReceptor blockersHeart failureWalk testQuestionnaire scoresΒ-blockersEnzyme inhibitorsAssist deviceGuideline-directed medical therapyAngiotensin-converting enzyme inhibitorMechanically Assisted Circulatory SupportHeart failure regimenLeft ventricular assist deviceAdvanced heart failureRetrospective cohort analysisContinuous-flow LVADBetter survival rateOutcomes of interestInteragency RegistryTriple therapyQuality of Care for Patients Hospitalized for Heart Failure in China
Gupta A, Yu Y, Tan Q, Liu S, Masoudi FA, Du X, Zhang J, Krumholz HM, Li J. Quality of Care for Patients Hospitalized for Heart Failure in China. JAMA Network Open 2020, 3: e1918619. PMID: 31913489, PMCID: PMC6991250, DOI: 10.1001/jamanetworkopen.2019.18619.Peer-Reviewed Original ResearchConceptsQuality of careHospital levelHF careEligible patientsComposite performance scoreEvidence-based β-blockersAngiotensin-converting enzyme inhibitorRetrospective cross-sectional studyVentricular ejection fraction assessmentMedian rateAngiotensin receptor blockersMedian patient ageHeart failure epidemicCross-sectional studyEjection fraction assessmentMedian odds ratioPerformance scoresHF hospitalizationReceptor blockersPatient ageHeart failureHospital admissionMedical recordsOdds ratioMAIN OUTCOME
2018
DPP (Dipeptidyl Peptidase)-4 Inhibition Potentiates the Vasoconstrictor Response to NPY (Neuropeptide Y) in Humans During Renin-Angiotensin-Aldosterone System Inhibition
Hubers SA, Wilson JR, Yu C, Nian H, Grouzmann E, Eugster P, Shibao CA, Billings FT, Jafarian Kerman S, Brown NJ. DPP (Dipeptidyl Peptidase)-4 Inhibition Potentiates the Vasoconstrictor Response to NPY (Neuropeptide Y) in Humans During Renin-Angiotensin-Aldosterone System Inhibition. Hypertension 2018, 72: 712-719. PMID: 29987109, PMCID: PMC6202157, DOI: 10.1161/hypertensionaha.118.11498.Peer-Reviewed Original ResearchConceptsNPY infusionPlacebo-controlled crossover studyAngiotensin-converting enzyme inhibitorAldosterone system inhibitionDose-dependent vasoconstrictionIntra-arterial enalaprilatAngiotensin receptor blockersForearm blood flowHigh-risk patientsOrder of treatmentReceptor blockersVasoconstrictor effectVasoconstrictor responsesCardiovascular effectsRenin-AngiotensinBrachial arteryHeart failureNorepinephrine releaseCrossover studyEndogenous NPYY1 receptorCrossover treatmentSystem inhibitionY2 receptorsDPP4 inhibitionHypertension Canada’s 2018 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults and Children
Nerenberg KA, Zarnke KB, Leung AA, Dasgupta K, Butalia S, McBrien K, Harris KC, Nakhla M, Cloutier L, Gelfer M, Lamarre-Cliche M, Milot A, Bolli P, Tremblay G, McLean D, Padwal RS, Tran KC, Grover S, Rabkin SW, Moe GW, Howlett JG, Lindsay P, Hill MD, Sharma M, Field T, Wein TH, Shoamanesh A, Dresser GK, Hamet P, Herman RJ, Burgess E, Gryn SE, Grégoire JC, Lewanczuk R, Poirier L, Campbell TS, Feldman RD, Lavoie KL, Tsuyuki RT, Honos G, Prebtani APH, Kline G, Schiffrin EL, Don-Wauchope A, Tobe SW, Gilbert RE, Leiter LA, Jones C, Woo V, Hegele RA, Selby P, Pipe A, McFarlane PA, Oh P, Gupta M, Bacon SL, Kaczorowski J, Trudeau L, Campbell NRC, Hiremath S, Roerecke M, Arcand J, Ruzicka M, Prasad GVR, Vallée M, Edwards C, Sivapalan P, Penner SB, Fournier A, Benoit G, Feber J, Dionne J, Magee LA, Logan AG, Côté AM, Rey E, Firoz T, Kuyper LM, Gabor JY, Townsend RR, Rabi DM, Daskalopoulou SS, Canada H. Hypertension Canada’s 2018 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults and Children. Canadian Journal Of Cardiology 2018, 34: 506-525. PMID: 29731013, DOI: 10.1016/j.cjca.2018.02.022.Peer-Reviewed Original ResearchConceptsBlood pressure monitoringTreatment of hypertensionBlood pressurePressure monitoringGuideline-directed heart failure therapyAmbulatory blood pressure monitoringHome blood pressure monitoringAngiotensin-converting enzyme inhibitorGlobal cardiovascular riskLarge arm circumferenceSetting of thrombolysisAngiotensin receptor blockersAcute ischemic strokeWhite-coat effectHeart failure therapyLower blood pressureUpper arm deviceEvidence-based guidelinesHypertension CanadaHypertension guidelinesReceptor blockersCardiovascular riskFailure therapyIschemic strokeHeart failurePrior Medications and the Cardiovascular Benefits From Combination Angiotensin‐Converting Enzyme Inhibition Plus Calcium Channel Blockade Among High‐Risk Hypertensive Patients
Brook RD, Kaciroti N, Bakris G, Dahlöf B, Pitt B, Velazquez E, Weber M, Zappe DH, Hau T, Jamerson KA. Prior Medications and the Cardiovascular Benefits From Combination Angiotensin‐Converting Enzyme Inhibition Plus Calcium Channel Blockade Among High‐Risk Hypertensive Patients. Journal Of The American Heart Association 2018, 7: e006940. PMID: 29301757, PMCID: PMC5778960, DOI: 10.1161/jaha.117.006940.Peer-Reviewed Original ResearchMeSH KeywordsAgedAmlodipineAngiotensin-Converting Enzyme InhibitorsAntihypertensive AgentsBenzazepinesBlood PressureCalcium Channel BlockersCause of DeathDrug Therapy, CombinationFemaleHumansHydrochlorothiazideHypertensionMaleMiddle AgedRandomized Controlled Trials as TopicRisk AssessmentRisk FactorsSodium Chloride Symporter InhibitorsTime FactorsTreatment OutcomeConceptsHigh-risk hypertensive patientsCardiovascular risk reductionHypertensive patientsAntihypertensive regimenCombination therapyBlood pressure control statusGreater cardiovascular risk reductionRenin-angiotensin system blockadeAngiotensin-converting enzyme inhibitorPrimary composite eventsPrior antihypertensive therapyPrimary composite outcomeCalcium channel blockadeLipid-lowering medicationsPrior medication useCalcium channel blockersRisk reductionACCOMPLISH trialAntihypertensive therapySystem blockadeCardiovascular benefitsCombination regimenComposite outcomeDrug regimensMedication use
2017
Angiotensin-converting Enzyme Inhibitor and Other Drug-associated Angioedema
Stone C, Brown NJ. Angiotensin-converting Enzyme Inhibitor and Other Drug-associated Angioedema. Immunology And Allergy Clinics Of North America 2017, 37: 483-495. PMID: 28687104, DOI: 10.1016/j.iac.2017.04.006.Peer-Reviewed Original ResearchConceptsDrug-induced angioedemaEnzyme inhibitorsAngiotensin-converting enzyme inhibitorNon-β-lactam antibioticsNonsteroidal antiinflammatory agentsNonallergic angioedemaSubstance PTherapeutic decisionsAngioedemaAntiinflammatory agentsLactam antibioticsOther DrugΒ-lactam antibioticsDrugsPatientsLeukotrienesBradykininGenetic variantsAntibioticsInhibitorsAngiotensinProstaglandinsAgentsHistamineMainstay
2016
The Importance of Worsening Heart Failure in Ambulatory Patients Definition, Characteristics, and Effects of Amino-Terminal Pro-B-Type Natriuretic Peptide Guided Therapy
Mallick A, Gandhi PU, Gaggin HK, Ibrahim N, Januzzi JL. The Importance of Worsening Heart Failure in Ambulatory Patients Definition, Characteristics, and Effects of Amino-Terminal Pro-B-Type Natriuretic Peptide Guided Therapy. JACC Heart Failure 2016, 4: 749-755. PMID: 27179830, DOI: 10.1016/j.jchf.2016.03.012.Peer-Reviewed Original ResearchMeSH KeywordsAcute DiseaseAdrenergic beta-AntagonistsAgedAmbulatory CareAngiotensin-Converting Enzyme InhibitorsCardiovascular DiseasesDisease ProgressionFemaleHeart FailureHospitalizationHumansMaleMiddle AgedMineralocorticoid Receptor AntagonistsNatriuretic Peptide, BrainPatient Care PlanningPeptide FragmentsProportional Hazards ModelsSodium Potassium Chloride Symporter InhibitorsStandard of CareTreatment OutcomeConceptsHeart failureChronic HFrEFNT-proBNPEjection fractionN-terminal pro-B-type natriuretic peptide concentrationsHigher loop diuretic dosesAngiotensin-converting enzyme inhibitorB-type natriuretic peptideAmbulatory heart failureAmino-Terminal ProJugular venous distensionLoop diuretic dosesAcute heart failureDecompensated heart failureReduced ejection fractionEvent-free survivalNatriuretic peptide concentrationsHigher ejection fractionStandard of careRelevant clinical eventsDiuretic therapyHF managementCardiovascular deathDiuretic dosesVenous distensionTiming of First Postdischarge Follow-up and Medication Adherence After Acute Myocardial Infarction
Faridi KF, Peterson ED, McCoy LA, Thomas L, Enriquez J, Wang TY. Timing of First Postdischarge Follow-up and Medication Adherence After Acute Myocardial Infarction. JAMA Cardiology 2016, 1: 147. PMID: 27437885, DOI: 10.1001/jamacardio.2016.0001.Peer-Reviewed Original ResearchConceptsAcute myocardial infarctionMedication adherenceClinic visitsHospital dischargeMyocardial infarctionIntervention Outcomes Network RegistryPlatelet P2Y12 receptor inhibitorsAngiotensin-converting enzyme inhibitorAcute Coronary TreatmentFirst outpatient followImproved care transitionsP2Y12 receptor inhibitorsPostdischarge Follow-upAngiotensin receptor blockersSecondary prevention therapiesLong-term prognosisLow medication adherencePatient medication adherenceProportion of daysLower household incomeGuidelines hospitalsReceptor blockersAcute MIClinical characteristicsCoronary Treatment
2014
Prevalence of Guideline-Directed Medical Therapy Among Patients Receiving Cardiac Resynchronization Therapy Defibrillator Implantation in the National Cardiovascular Data Registry During the Years 2006 to 2008
Schneider PM, Pellegrini CN, Wang Y, Fein AS, Reynolds MR, Curtis JP, Masoudi FA, Varosy PD. Prevalence of Guideline-Directed Medical Therapy Among Patients Receiving Cardiac Resynchronization Therapy Defibrillator Implantation in the National Cardiovascular Data Registry During the Years 2006 to 2008. The American Journal Of Cardiology 2014, 113: 2052-2056. PMID: 24793671, PMCID: PMC4346333, DOI: 10.1016/j.amjcard.2014.03.049.Peer-Reviewed Original ResearchMeSH KeywordsAdrenergic beta-AntagonistsAged, 80 and overAngiotensin-Converting Enzyme InhibitorsCardiac Resynchronization TherapyCombined Modality TherapyDeath, Sudden, CardiacDefibrillators, ImplantableFemaleFollow-Up StudiesHeart FailureHumansMaleMiddle AgedPractice Guidelines as TopicPrevalenceRegistriesRetrospective StudiesRisk AssessmentSurvival AnalysisTreatment OutcomeUnited StatesVentricular Dysfunction, LeftConceptsGuideline-directed medical therapyCardiac resynchronization therapyImplantable Cardioverter-Defibrillator RegistryAngiotensin II receptor inhibitorΒ-blockersMedical therapyClass IReceptor inhibitorsNational Cardiovascular Data Registry Implantable Cardioverter Defibrillator RegistryCardiac resynchronization therapy defibrillator implantationLeft ventricular systolic dysfunctionSevere heart failure symptomsAngiotensin-converting enzyme inhibitorNational Cardiovascular Data RegistryClass I indicationsCRT-D implantationHeart failure symptomsVentricular systolic dysfunctionProportion of patientsSelection of patientsReal-world patientsAngiotensin-converting enzymePrevalence of guidelinesContemporaneous guidelinesQuality improvement targets
2013
Temporal Trends in Quality of Care Among Recipients of Implantable Cardioverter-Defibrillators
Dodson JA, Lampert R, Wang Y, Hammill SC, Varosy P, Curtis JP. Temporal Trends in Quality of Care Among Recipients of Implantable Cardioverter-Defibrillators. Circulation 2013, 129: 580-586. PMID: 24192798, PMCID: PMC3946506, DOI: 10.1161/circulationaha.113.003747.Peer-Reviewed Original ResearchConceptsOptimal medical therapyCardiac resynchronization therapyAdverse eventsEligible patientsQuality of careICD RegistryPotential confoundersNew York Heart Association class III/IVClass III/IVAngiotensin-converting enzyme inhibitorAngiotensin receptor blockersVentricular ejection fractionNew ICD implantsImplantable cardioverter defibrillatorHierarchical logistic regressionCRT eligibilityReceptor blockersEjection fractionMedical therapyResynchronization therapyICD implantsObservational studyCardioverter defibrillatorΒ-blockersPatientsPreoperative angiotensin-converting enzyme inhibitors and angiotensin receptor blocker use and acute kidney injury in patients undergoing cardiac surgery
Coca SG, Garg AX, Swaminathan M, Garwood S, Hong K, Thiessen-Philbrook H, Passik C, Koyner JL, Parikh CR, Consortium O, Jai R, Jeevanandam V, Akhter S, Devarajan P, Bennett M, Edelsteinm C, Patel U, Chu M, Goldbach M, Guo L, McKenzie N, Myers M, Novick R, Quantz M, Zappitelli M, Dewar M, Darr U, Hashim S, Elefteriades J, Geirsson A. Preoperative angiotensin-converting enzyme inhibitors and angiotensin receptor blocker use and acute kidney injury in patients undergoing cardiac surgery. Nephrology Dialysis Transplantation 2013, 28: 2787-2799. PMID: 24081864, PMCID: PMC3811062, DOI: 10.1093/ndt/gft405.Peer-Reviewed Original ResearchMeSH KeywordsAcute Kidney InjuryAdultAgedAngiotensin Receptor AntagonistsAngiotensin-Converting Enzyme InhibitorsBiomarkersCardiac Surgical ProceduresCoronary Artery DiseaseFemaleHumansIncidenceKidney Function TestsMaleMiddle AgedPreoperative CarePrognosisProspective StudiesReceptors, AngiotensinUnited StatesConceptsStructural acute kidney injuryAcute kidney injuryAngiotensin-converting enzyme inhibitorAngiotensin receptor blockersACEI/angiotensin receptor blockerACEI/ARB exposureKidney injurySerum creatinineARB exposureCardiac surgeryUrinary biomarkersEnzyme inhibitorsPreoperative angiotensin-converting enzyme inhibitorACEI/ARB usageAngiotensin receptor blocker useFunctional acute kidney injuryPostoperative acute kidney injuryACEI/ARB useAKI stage 1New urinary biomarkersMorning of surgeryReceptor blocker useCo-primary outcomesProspective cohort studyARB usage
2012
Angiotensin-converting enzyme inhibition or mineralocorticoid receptor blockade do not affect prevalence of atrial fibrillation in patients undergoing cardiac surgery*
Pretorius M, Murray KT, Yu C, Byrne JG, Billings FT, Petracek MR, Greelish JP, Hoff SJ, Ball SK, Mishra V, Body SC, Brown NJ. Angiotensin-converting enzyme inhibition or mineralocorticoid receptor blockade do not affect prevalence of atrial fibrillation in patients undergoing cardiac surgery*. Critical Care Medicine 2012, 40: 2805-2812. PMID: 22824930, PMCID: PMC3588582, DOI: 10.1097/ccm.0b013e31825b8be2.Peer-Reviewed Original ResearchConceptsAcute renal failureAngiotensin-converting enzyme inhibitorMineralocorticoid receptor blockadePostoperative atrial fibrillationMineralocorticoid receptor antagonistsAtrial fibrillationPlacebo groupSpironolactone groupRenal failureCardiac surgeryReceptor blockadeReceptor antagonistEnzyme inhibitorsDouble-blind placebo-controlled studyAngiotensin-Converting Enzyme InhibitionPrevalence of hypotensionElective cardiac surgeryPlacebo-controlled studyRenin-angiotensin systemNormal sinus rhythmEnzyme inhibitionRamipril groupSpironolactone useHospital stayPrimary endpoint
2010
Who is missing from the measures? Trends in the proportion and treatment of patients potentially excluded from publicly reported quality measures
Bernheim SM, Wang Y, Bradley EH, Masoudi FA, Rathore SS, Ross JS, Drye E, Krumholz HM. Who is missing from the measures? Trends in the proportion and treatment of patients potentially excluded from publicly reported quality measures. American Heart Journal 2010, 160: 943-950.e5. PMID: 21095284, PMCID: PMC3319386, DOI: 10.1016/j.ahj.2010.06.046.Peer-Reviewed Original ResearchMeSH KeywordsAdrenergic beta-AntagonistsAgedAngiotensin-Converting Enzyme InhibitorsCross-Sectional StudiesFemaleHospitalizationHumansMaleMedicaidMedicareMyocardial InfarctionOutcome and Process Assessment, Health CarePlatelet Aggregation InhibitorsPrognosisQuality ImprovementQuality Indicators, Health CareRetrospective StudiesUnited StatesConceptsAcute myocardial infarctionProportion of patientsRelative contraindicationAngiotensin-converting enzyme inhibitorTreatment of patientsMedicaid Services core measuresQuality improvement projectPublic reportingCross-sectional analysisMyocardial infarctionMedicare patientsHospital careΒ-blockersAMI admissionsPatientsInsufficient evidenceEnzyme inhibitorsTreatment ratesBetter careContraindicationsMedicaid ServicesData cohortCore measuresTreatmentImprovement project
2008
Mental Disorders, Quality of Care, and Outcomes Among Older Patients Hospitalized With Heart Failure: An Analysis of the National Heart Failure Project
Rathore SS, Wang Y, Druss BG, Masoudi FA, Krumholz HM. Mental Disorders, Quality of Care, and Outcomes Among Older Patients Hospitalized With Heart Failure: An Analysis of the National Heart Failure Project. JAMA Psychiatry 2008, 65: 1402-1408. PMID: 19047527, PMCID: PMC2790277, DOI: 10.1001/archpsyc.65.12.1402.Peer-Reviewed Original ResearchConceptsMental illness diagnosisACE inhibitor prescriptionHeart failureMultivariate adjustmentQuality of careIllness diagnosisInhibitor prescriptionLVEF evaluationMental illnessNational Heart Failure ProjectAngiotensin-converting enzyme inhibitorVentricular ejection fraction assessmentUS acute care hospitalsLeft ventricular ejection fraction assessmentHeart Failure ProjectAcute care hospitalsHigher crude ratesEjection fraction assessmentPopulation-based sampleEligible patientsTreatment contraindicationsCause readmissionElderly patientsOlder patientsCare hospital
2006
Trends in Acute Myocardial Infarction in 4 US States Between 1992 and 2001
Masoudi FA, Foody JM, Havranek EP, Wang Y, Radford MJ, Allman RM, Gold J, Wiblin RT, Krumholz HM. Trends in Acute Myocardial Infarction in 4 US States Between 1992 and 2001. Circulation 2006, 114: 2806-2814. PMID: 17145994, DOI: 10.1161/circulationaha.106.611707.Peer-Reviewed Original ResearchConceptsAcute myocardial infarctionAngiotensin-converting enzyme inhibitorEnzyme inhibitorsPrimary discharge diagnosisHealth system perspectiveQuality of careMore comorbiditiesClinical characteristicsDischarge diagnosisMyocardial infarctionAMI careMedicare patientsMultivariable modelTreatment criteriaMedicare populationTreatment ratesAspirinHealth impactsMortalityCarePresent studyOutcomesIndicator definitionsDiverse populationsInhibitorsAn Inducible Mouse Model for PAX2-Dependent Glomerular Disease: Insights into a Complex Pathogenesis
Wagner KD, Wagner N, Guo JK, Elger M, Dallman MJ, Bugeon L, Schedl A. An Inducible Mouse Model for PAX2-Dependent Glomerular Disease: Insights into a Complex Pathogenesis. Current Biology 2006, 16: 793-800. PMID: 16631587, DOI: 10.1016/j.cub.2006.02.072.Peer-Reviewed Original ResearchConceptsInducible mouse modelGlomerular diseaseMouse modelAngiotensin-converting enzyme inhibitorEnd-stage renal failureTreatment of miceHealthy adult animalsRenal failureRenal functionRenal diseaseComplex pathogenesisNephrin expressionEnzyme inhibitorsDiseaseAdult animalsPodocytesDedifferentiated phenotypePersistent expressionMature podocytesPAX2MicePax genesFunctional relevanceTranscriptional repressorActivation
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply